TNF and deep vein thrombosis: In an ad hoc safety analysis (data cutoff February 2019), the IRs per 100 person-years in the treatments with tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, and TNF inhibitors were 0.30, 0.38, and 0.18 for DVT and 0.27, 0.54, and 0.09 for PE, respectively.